The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Open accessAbstract
B cells are increasingly recognized as playing an important role in the ongoing control of hepatitis B virus (HBV). The development of antibodies against the viral surface antigen (HBV surface antigen [HBsAgs]) constitutes the hallmark of resolution of acute infection and is a therapeutic goal for functional cure of chronic HBV (CHB). We characterized B cells directly ex vivo from the blood and liver of patients with CHB to investigate constraints on their antiviral potential. Unexpectedly, we found that HBsAg-specific B cells persisted in the blood and liver of many patients with CHB and were enriched for T-bet, a signature of antiviral potential in B cells. However, purified, differentiated HBsAg-specific B cells from patients with CHB had defective antibody production, consistent with undetectable anti-HBs antibodies in vivo. HBsAg-specific and global B cells had an accumulation of CD21-CD27- atypical memory B cells (atMBC) with high expression of inhibitory receptors, including PD-1. These atMBC demonstrated altered signaling, homing, differentiation into antibody-producing cells, survival, and antiviral/proinflammatory cytokine production that could be partially rescued by PD-1 blockade. Analysis of B cells within healthy and HBV-infected livers implicated the combination of this tolerogenic niche and HBV infection in driving PD-1hiatMBC and impairing B cell immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Razavi-Shearer, D., Gamkrelidze, I., Nguyen, M. H., Chen, D.-S., Van Damme, P., Abbas, Z., Abdulla, M., Abou Rached, A., Adda, D., Aho, I., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30056-6 · Cited by 1,661
Regulatory B Cells: Origin, Phenotype, and Function
Rosser, E. C., & Mauri, C. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.005 · Cited by 1,455
Self-citationIntracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes
Guidotti, L. G., Ishikawa, T., Hobbs, M. V., Matzke, B., Schreiber, R., & Chisari, F. V. (1996) · Immunity · doi:10.1016/s1074-7613(00)80295-2 · Cited by 1,083
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Moir, S., Ho, J., Malaspina, A., Wang, W., DiPoto, A. C., O'Shea, M. A., Roby, G., Kottilil, S., Arthos, J., Proschan, M. A., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072683 · Cited by 901
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Muraguchi, A., Hirano, T., Tang, B., Matsuda, T., Horii, Y., Nakajima, K., & Kishimoto, T. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.332 · Cited by 783
Cited by
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Immunobiology and pathogenesis of hepatitis B virus infection
Iannacone, M., & Guidotti, L. G. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00549-4 · Cited by 520
Salimzadeh, L., Le Bert, N., Dutertre, C.-A., Gill, U. S., Newell, E. W., Frey, C., Hung, M., Novikov, N., Fletcher, S., Kennedy, P. T. F., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121957 · Cited by 290
Self-citationHow to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong, G. L. H., Gane, E., & Lok, A. S. F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.024 · Cited by 272
HBV-Induced Immune Imbalance in the Development of HCC
Chen, Y., & Tian, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02048 · Cited by 270
Metadata
- Authors
- Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdyte, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., Mauri, C., Blair, P. A., Pelletier, N., & Maini, M. K.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-08-09
- Volume
- 128
- Issue
- 10
- Pages
- 4588-4603
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2886930165
- Cited by
- 330
- References
- 68
- FWCI
- 21.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating and intrahepatic antiviral B cells are defective in hepatitis B. https://app.cochat.ai/papers/10.1172/jci121960
- The paper
- Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdyte, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., Mauri, C., Blair, P. A., Pelletier, N., & Maini, M. K. (2018). Circulating and intrahepatic antiviral B cells are defective in hepatitis B. Journal of Clinical Investigation. https://doi.org/10.1172/jci121960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.